[go: up one dir, main page]

MX2024002904A - Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. - Google Patents

Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.

Info

Publication number
MX2024002904A
MX2024002904A MX2024002904A MX2024002904A MX2024002904A MX 2024002904 A MX2024002904 A MX 2024002904A MX 2024002904 A MX2024002904 A MX 2024002904A MX 2024002904 A MX2024002904 A MX 2024002904A MX 2024002904 A MX2024002904 A MX 2024002904A
Authority
MX
Mexico
Prior art keywords
adults
synthetic
treatment
cannabidiol
focal epilepsy
Prior art date
Application number
MX2024002904A
Other languages
English (en)
Inventor
John Messenheimer
Donna Gutterman
Terri Sebree
Ted Smith
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Publication of MX2024002904A publication Critical patent/MX2024002904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente tecnología se refiere a un método para reducir la frecuencia de las crisis de epilepsia en un sujeto que tiene epilepsia, por medio de la administración por la vía transdérmica de una cantidad eficaz de cannabidiol (CBD) al sujeto, en donde se reduce la frecuencia de las crisis de epilepsia.
MX2024002904A 2017-09-19 2020-03-18 Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. MX2024002904A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560446P 2017-09-19 2017-09-19
US201762593575P 2017-12-01 2017-12-01
US201862613160P 2018-01-03 2018-01-03
US201862652995P 2018-04-05 2018-04-05
US201862660198P 2018-04-19 2018-04-19

Publications (1)

Publication Number Publication Date
MX2024002904A true MX2024002904A (es) 2024-04-04

Family

ID=63762572

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003004A MX2020003004A (es) 2017-09-19 2018-09-18 Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
MX2024002904A MX2024002904A (es) 2017-09-19 2020-03-18 Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003004A MX2020003004A (es) 2017-09-19 2018-09-18 Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.

Country Status (11)

Country Link
US (4) US20190083388A1 (es)
EP (1) EP3684411A1 (es)
JP (2) JP2020534362A (es)
KR (1) KR20200055067A (es)
AU (1) AU2018337933A1 (es)
BR (1) BR112020004947A2 (es)
CA (1) CA3075719A1 (es)
IL (2) IL301910A (es)
JO (1) JOP20200045A1 (es)
MX (2) MX2020003004A (es)
WO (1) WO2019058261A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733156A1 (de) * 2019-05-02 2020-11-04 Gábor Fóti C.b.d.m therapie
CA3150617A1 (en) * 2019-09-17 2021-03-25 Terri Sebree Treatment of syngap1 encephalopathy
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CA3155176A1 (en) * 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
EP4196114A4 (en) * 2020-08-17 2024-10-30 Pike Therapeutics, Inc. TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
MX2023006551A (es) * 2020-12-03 2023-08-17 Zynerba Pharmaceuticals Inc Tratamiento de las convulsiones refractarias.
CA3213953A1 (en) * 2021-04-08 2022-10-13 Fotios M. Plakogiannis Pharmaceutical composition and method for treating seizure disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
DK2473475T3 (en) * 2009-08-31 2017-06-26 Zynerba Pharmaceuticals Inc APPLICATION OF CANNABIDIOL PRODUCTS IN TOPIC AND TRANSDERMAL MICROWAVE ADMINISTRATION
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
EP3684411A1 (en) 2020-07-29
CA3075719A1 (en) 2019-03-28
MX2020003004A (es) 2020-11-06
JP7650929B2 (ja) 2025-03-25
US20210030665A1 (en) 2021-02-04
AU2018337933A1 (en) 2020-03-12
US20250302734A1 (en) 2025-10-02
US20190083388A1 (en) 2019-03-21
WO2019058261A9 (en) 2019-07-04
JOP20200045A1 (ar) 2020-02-27
JP2023171776A (ja) 2023-12-05
IL272818A (en) 2020-04-30
JP2020534362A (ja) 2020-11-26
US20250213465A1 (en) 2025-07-03
WO2019058261A1 (en) 2019-03-28
KR20200055067A (ko) 2020-05-20
BR112020004947A2 (pt) 2020-09-15
IL301910A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2024002904A (es) Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
MX2022012424A (es) Tratamiento del sindrome del cromosoma x fragil con canabidiol.
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
MX2020006954A (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
MX367338B (es) Uso de cannabinoides para el tratamiento de epilepsia.
PH12015502075A1 (en) Treatment of cataplexy
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2018015100A (es) Composicion y metodo para reducir la neutropenia.
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
PH12017500933A1 (en) Sublingual administration of riluzole
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
MX394355B (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
EA201790332A1 (ru) Дополнительная терапия 25-гидроксивитамином d
MX2017006446A (es) Administracion sublingual de riluzol.
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
MX2018000274A (es) Bacterias oxidantes de amoniaco para el tratamiento del acne.
CO2022000064A2 (es) Dosificación modificada de tocilizumab subcutáneo para la artritis reumatoide
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
BR112018069174A2 (pt) tratamento de prurido urêmico
MX2016002307A (es) Tratamiento para el cancer.
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.